Non-squamous, Non-Small Cell Lung Cancer: Clinical Trials

4 completed, 1 recruiting. 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	1	Recruiting 1

Follow Non-squamous, Non-Small Cell Lung Cancer: new trials by email Literature Review of Non-squamous, Non-Small Cell Lung Cancer trials Research Report on Non-squamous, Non-Small Cell Lung Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab - Non-squamous, Non-Small Cell Lung Cancer	Phase 3	Recruiting	Candel Therapeutics, Inc.	500	2026-06-15	2026-06-22
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma afatinib - Non-squamous, Non-Small Cell Lung Cancer		Completed	Boehringer Ingelheim	805	2021-08-26	2024-12-27
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. Afatinib, other systemic therapy - Non-squamous, Non-Small Cell Lung Cancer		Completed	Boehringer Ingelheim	110	2020-10-15	2024-09-19
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer Afatinib - Non-squamous, Non-Small Cell Lung Cancer		Completed	Boehringer Ingelheim	72	2020-05-20	2025-02-28
The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), Gefitinib (IRESSA®) - Non-squamous, Non-Small Cell Lung Cancer		Completed	Boehringer Ingelheim	462	2019-12-17	2023-05-25

Narrower conditions

Carcinoma, Non-Small-Cell Lung (5)

Broader conditions

Bronchial Neoplasms (5)  ·  Carcinoma, Bronchogenic (5)  ·  Lung Diseases (5)  ·  Lung Neoplasms (5)  ·  Neoplasms (5)  ·  Neoplasms by Site (5)  ·  Respiratory Tract Diseases (5)  ·  Respiratory Tract Neoplasms (5)  ·  Thoracic Neoplasms (5)

Interventions

Afatinib (4)  ·  Docetaxel (1)  ·  Erlotinib Hydrochloride (1)  ·  Gefitinib (1)  ·  Valacyclovir (1)  ·  osimertinib (1)  ·  pembrolizumab (1)

Sponsors

Boehringer Ingelheim (4)  ·  Candel Therapeutics, Inc. (1)

Countries

United States (2)  ·  China (1)  ·  Japan (1)  ·  United Kingdom (1)

Results publications

PMID 35274704, PMID 40483538